This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Teijin Pharma Limited
Drug Names(s): KTP-001
Description: KTP-001 shares a structure with the matrix metalloproteinase (MMP), an enzyme that promotes the spontaneous regression of hernia. KTP-001 is expected to achieve the regression of lumbar disc herniation with simple injections following conventional surgery.
Deal Structure: KTP-001 was developed jointly by Teijin Pharma and KAKETSUKEN (The Chemo-Sero-Therapeutic Research Institute).
Additional information available to subscribers only: